Moderna Advances Hantavirus Vaccine as Cruise Ship Outbreak Raises Global Concern

Pharmaceutical giant Moderna is reportedly working alongside an international team of scientists to develop a vaccine against hantavirus, a potentially deadly disease recently linked to multiple deaths aboard a cruise ship in the Atlantic Ocean.

The renewed urgency comes after an outbreak was reported on the expedition cruise vessel MV Hondius, which departed from Argentina last month. According to the latest update from the World Health Organization (WHO), eight cases of hantavirus have been identified among individuals connected to the ship, including three confirmed infections and five suspected cases.

Health officials are still investigating the source of the outbreak, as hantavirus is most commonly transmitted through exposure to infected rodents or their droppings. At this stage, authorities have not confirmed how the virus made its way onto the vessel, nor whether infections have spread beyond passengers and crew members.

The outbreak has already been linked to three deaths, although only one of the deceased has been officially confirmed as a hantavirus case. Among the victims was a Dutch woman who disembarked from the MV Hondius during a stop at Saint Helena on April 24 before traveling to South Africa, where she died two days later. Her husband had earlier died aboard the ship on April 11, though his case has not been confirmed as related to hantavirus.

As concerns grow over the virus, scientists are accelerating efforts to create a vaccine that could prevent future outbreaks and reduce severe complications linked to infection.

Leading part of this effort is Professor Asel Sartbaeva, a chemist at the University of Bath, who is collaborating with experts in the United States and South Africa on a vaccine candidate that was already under development before the cruise ship incident.

Professor Sartbaeva explained that creating an effective vaccine would be a major breakthrough in preventing severe disease outcomes. She also highlighted a new technology called ensilication, which her research team has spent more than 15 years developing.

Unlike many traditional vaccines that require freezing temperatures during transportation and storage, ensilication allows vaccines to be coated in ultra-thin layers of inorganic material, making them far more stable under varying temperatures.

This innovation could significantly improve vaccine accessibility, particularly in remote or underdeveloped regions where cold-chain storage remains a major challenge. According to Sartbaeva, the technology could even make it possible to distribute vaccines through drone deliveries without the need for specialized refrigeration.

The research project combines efforts from a Texas-based team that developed the hantavirus antigen with South African partners, including biotechnology company Afrigen, which is supporting vaccine development and testing.

Hantavirus infections are relatively rare but can be extremely dangerous, causing severe respiratory and kidney complications in humans. Symptoms often begin with fever, fatigue, muscle aches, and headaches before progressing to more serious illness in severe cases.

While the outbreak aboard the MV Hondius remains under investigation, the incident has once again highlighted the growing importance of pandemic preparedness, rapid disease detection, and vaccine innovation.

With Moderna and international researchers now pushing forward on vaccine development, health experts are hopeful that a breakthrough could offer stronger protection against future hantavirus outbreaks worldwide.